Descripción del proyecto
Evolución unicelular en la leucemia linfoblástica aguda
Como muchos tipos de cáncer, la leucemia linfoblástica aguda (LLA, o ALL por sus siglas en inglés) presenta heterogeneidad genética, lo cual podría explicar la respuesta parcial a los tratamientos. El proyecto financiado con fondos europeos scTALLmap analizará el genoma y transcriptoma de células individuales de muestras de pacientes con LLA en el momento del diagnóstico, durante el tratamiento y en caso de recidiva. Este análisis contribuirá a desarrollar una visión general exhaustiva a nivel de célula única de la LLA y a obtener nuevos datos sobre el mecanismo de recidiva. Los investigadores utilizarán la heterogeneidad celular y la presencia de subclones de riesgo elevado en el diagnóstico para realizar la estratificación del riesgo de los pacientes. A la larga, esta información allanará el camino hacia la personalización de tratamientos dirigidos específicamente a los subclones de leucemia agresivos.
Objetivo
Spaniards have their daily siesta, Germans like sausages and Belgians love beer. Stereotypes can certainly be misleading, just like judging a cell by its membership to a particular cell type, the so-called population-based analysis. Nowadays we know that tumors are tremendously heterogeneous and, in the era of single-cell sequencing, we have the exquisite opportunity to study each individual cell with unprecedented resolution. Acute lymphoblastic leukemia (ALL), which is the most common cancer in children, shows extensive genetic intratumoral heterogeneity. This heterogeneity might be the underlying reason for an incomplete response to treatment and for the development of relapse. In order to envision its clinical implementation, it is essential to first i) generate a single-cell map and ii) accumulate evidence on how the subclonal composition affects the response to treatment. With this aim, I will build a comprehensive single-cell overview of the composition, development and response to therapy for the aggressive subtype T-cell ALL. I will perform integrative single-cell genome and transcriptome profiling of ex vivo carefully selected pediatric samples at diagnosis, during drug treatment and in case of relapse. This approach will provide realtime temporal information about the sensitivity of each cell type to the therapy and about how relapse can develop. I will use state-of-the-art single-cell technologies to which the host institute has early access. Moreover, I will apply my previous single-cell expertise and bring a unique mix of experimental and computational skills to the lab. The results of scTALLmap, will have significant impact in leukemia by paving the way for improved risk-stratification based on the cellular heterogeneity and the presence of high-risk subclones at diagnosis. Ultimately, it will permit the design of novel and more personalized therapeutic modalities sparing toxicity and targeting the full complement of leukemia subclones.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinador
9052 ZWIJNAARDE - GENT
Bélgica